{"commentary":{"count":155,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":71,"youtube":50,"podcast":28,"x_video":6},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04493853\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CAPItello-281","nct_id":"NCT04493853","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=capitello-281-nct04493853. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"CAPItello-281","arms":[{"description":"Participants receive capivasertib in combination with abiraterone (prednisone/prednisolone) on a background of ADT.","label":"Capivasertib + Abiraterone","type":"EXPERIMENTAL"},{"description":"Participants receive placebo in combination with abiraterone (prednisone/prednisolone) on a background of ADT.","label":"Placebo + Abiraterone","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-03-31","type":"ESTIMATED"},"conditions":["Hormone-Sensitive Prostate Cancer"],"enrollment":{"count":1012,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Capivasertib","type":"DRUG"},{"name":"Placebo","type":"OTHER"},{"name":"Abiraterone Acetate","type":"DRUG"}],"last_update":"2026-09-10","lead_sponsor":"AstraZeneca","official_title":"A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN Deficiency.","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-10-07","type":"ACTUAL"},"primary_outcomes":[{"measure":"Radiographic Progression-free Survival (rPFS)","timeFrame":"Tumor assessments every 16 weeks from randomisation until radiographic progression assessed by the investigator. The timing of the Primary analysis DCO for rPFS is approximately 49 months from the first subject randomized"}],"references":[{"citation":"Fizazi K, Clarke NW, De Santis M, Uemura H, Fay AP, Karadurmus N, Kwiatkowski M, Alvarez-Fernandez C, Jiang S, Sotelo M, Parslow D, Oliveira N, Kwon TG, Ye D, Boudewijns S, Danchaivijitr P, Rooney C, Gresty C, Yeste-Velasco M, Logan J, George DJ; CAPItello-281 Study Group. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol. 2026 Jan;37(1):53-68. doi: 10.1016/j.annonc.2025.10.004. Epub 2025 Oct 19.","pmid":"41120017","type":"DERIVED"}],"start_date":{"date":"2020-07-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency","url":"https://clinicaltrials.gov/study/NCT04493853"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/capitello-281-nct04493853"}